Streetbeat News

MEDXF

Medexus Pharmaceuticals Inc

https://www.medexusinc.com/

CEO

Kenneth D'Entremont

Industry

Medicinal and Botanical Manufacturing

Open

2.05

Mkt cap

49M

Volume

600

High

2.05

P/E Ratio

22.08

52-wk high

2.35

Low

1.95

Div yield

N/A

52-wk low

1.08

Medexus Pharmaceuticals has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance to make Trecondyv accessible to publicly funded drug programs in Canada.

Portfolio Pulse from

November 18, 2024 | 12:15 pm

Medexus Pharmaceuticals Inc. (MEDXF) held its Q2 2025 earnings call, discussing financial performance and future outlook. Key participants included CEO Ken d'Entremont and CFO Brendon Bushman.

Portfolio Pulse from

November 08, 2024 | 7:30 pm

Medexus Pharmaceuticals reported strong fiscal Q2 2025 results with $26.3 million in revenue, $0.1 million in net income, $1.6 million in operating income, and $6.0 million in Adjusted EBITDA. A conference call is scheduled for November 8, 2024.

Portfolio Pulse from

November 07, 2024 | 10:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.